Identifying a maximum tolerated contour in two-dimensional dose finding

DOI10.1002/SIM.6918MaRDI QIDQ7002166zbMATH OpenFDO

Authors Nolan A. Wages

Publication date 4 April 2025

Published in Statistics in Medicine (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1002/SIM.6918

zbMATH Keywords

dose findingdrug combinationequivalence contourphase I

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Cites work

• A dose-finding approach based on shrunken predictive probability for combinations of two agents in phase I trials
• A product of independent beta probabilities dose escalation design for dual-agent phase I trials
• Characterization of the likelihood continual reassessment method
• Consistency of continual reassessment method under model misspecification
• Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
• Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control
• Dose-finding with two agents in phase I oncology trials
• scientific article; zbMATH DE number 3444596 (Why is no real title available?)
• Model Selection: An Integral Part of Inference
• Two‐Dimensional Dose Finding in Discrete Dose Space

Cited in

(2)

• A design for phase I trials in completely or partially ordered groups
• Preface. Early phase dose finding methodology

This page was built for publication: Identifying a maximum tolerated contour in two-dimensional dose finding

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q7002166)